EQS-Adhoc: Nakiki SE: Review of a potential claim of approximately EUR 30 million
Werte in diesem Artikel
|
EQS-Ad-hoc: NAKIKI SE / Key word(s): Sales Result/Miscellaneous Werbung
Nakiki SE announces that a claim of approximately EUR 30 million arising from the supply of COVID masks during the corona pandemic is being examined as part of a litigation financing enquiry. The potential option volume, i.e. the amount to which the company (or the financing subsidiary) is entitled if the litigation financing agreement is concluded and the case is won, is up to EUR 15 million. The Federal Republic of Germany alone, represented by the Federal Ministry of Health, has been sued more than 100 times in connection with the supply of COVID masks, with a value in dispute of more than 1 billion euros. According to press reports, some of these cases have been settled with a partial payment.NAKIKI SE, in future Legal Finance Holding SE Werbung
End of Inside Information
09-May-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Nakiki SE |
| Johnsallee 30 | |
| 20148 Hamburg | |
| Germany | |
| E-mail: | info@nakikifinance.com |
| Internet: | https://nakikifinance.com/ |
| ISIN: | DE000WNDL300, DE000WNDL318 |
| WKN: | WNDL30, WNDL31 |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1899769 |
| End of Announcement | EQS News Service |
|
|
1899769 09-May-2024 CET/CEST
Ausgewählte Hebelprodukte auf NAKIKI
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf NAKIKI
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle NAKIKI Aktie News
NAKIKI Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für NAKIKI nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
Keine Analysen gefunden.